Alphatec Holdings (ATEC) AI Stock Analysis

• Market Cap: $2.91B
• Dividend Yield: N/A
• Average Volume (3M): 2.66M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: 27.11%
• EPS Growth: 17.66%
• Country: US
• Employees: 867
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.03
• Shares Outstanding: 148,550,190
• 10 Day Avg. Volume: 2,364,604
• 30 Day Avg. Volume: 2,664,693
• PEG Ratio: 0.30
• Price to Book (P/B): 139.10
• Price to Sales (P/S): 2.15
• P/FCF Ratio: -9.52
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 3.65
• Enterprise Value/Gross Profit: 5.28
• Enterprise Value/Ebitda: -50.95
• 1Y Price Target: $22.82
• Price Target Upside: 16.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): 0.01
• Revenue Forecast (FY): $758.74M

• Rating: 58 Neutral
• Price Target: $19.50 ▼(-0.56% Downside)

The overall stock score is primarily influenced by strong earnings call results, showcasing significant revenue growth and improved guidance. However, financial performance is weighed down by high leverage and negative profitability, and valuation metrics are unattractive due to a negative P/E ratio. Technical analysis indicates strong momentum, but caution is advised due to potential overbought conditions.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market presence and successful product adoption, supporting long-term business expansion.

Product Expansion

Expanding product lines enhance competitive positioning and address diverse market needs, driving sustainable growth.

Cash Position

A strong cash position provides financial flexibility to invest in growth opportunities and manage economic uncertainties.

Negative Factors

High Leverage

High leverage increases financial risk and limits the company's ability to invest in growth or weather economic downturns.

Profitability Challenges

Ongoing profitability issues can hinder reinvestment in the business and affect long-term financial health.

Negative Free Cash Flow

Negative free cash flow limits the company's ability to fund operations internally, potentially affecting future growth.

Alphatec Holdings Business Overview & Revenue Model

Company Description

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.

How the Company Makes Money

Alphatec Holdings generates revenue primarily through the sale of its spinal surgery products, which include surgical implants, instruments, and biologics. The company operates on a model that combines direct sales to hospitals and healthcare providers with partnerships with distributors and surgical centers. Key revenue streams include sales of spinal fusion devices, motion preservation products, and surgical instruments used in various spinal procedures. Additionally, ATEC may benefit from strategic partnerships with healthcare professionals and institutions that facilitate the adoption of its products in clinical settings, leading to increased sales and market penetration.

Alphatec Holdings Financial Statement Overview

Summary

Alphatec Holdings shows revenue growth but faces significant challenges in profitability and cash flow management. High leverage and negative equity increase financial risk, while declining cash flow metrics highlight liquidity concerns.

Income Statement

Alphatec Holdings shows a positive revenue growth trend with a 6.22% increase in TTM, indicating potential market expansion. However, the company struggles with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin remains relatively strong at around 68.8%, but the persistent negative net income and EBIT margins highlight ongoing operational challenges.

Balance Sheet

The balance sheet reveals significant financial leverage with a high debt-to-equity ratio of 12.38 in TTM, indicating potential financial risk. The negative return on equity suggests inefficiencies in generating returns for shareholders. The equity ratio is low, reflecting a heavy reliance on debt financing, which could pose risks if market conditions change.

Cash Flow

Cash flow analysis shows a concerning decline in free cash flow growth by 65.07% in TTM, indicating potential liquidity issues. The operating cash flow to net income ratio is low, suggesting challenges in converting earnings into cash. The negative free cash flow to net income ratio further underscores the company's struggle to generate positive cash flow from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	728.02M	611.56M	482.26M	350.87M	243.21M	144.86M
Gross Profit	503.99M	424.26M	310.20M	233.06M	157.76M	102.50M
EBITDA	-52.22M	-53.87M	-110.59M	-102.58M	-106.88M	-54.84M
Net Income	-154.96M	-162.12M	-186.64M	-151.29M	-143.03M	-78.99M
Balance Sheet
Total Assets	787.25M	775.71M	805.21M	520.97M	572.05M	265.22M
Cash, Cash Equivalents and Short-Term Investments	155.74M	138.84M	220.97M	84.70M	187.25M	107.77M
Total Debt	591.15M	609.94M	541.68M	395.86M	355.43M	43.16M
Total Liabilities	775.74M	766.28M	703.49M	555.63M	492.63M	107.74M
Stockholders Equity	11.51M	9.43M	101.72M	-34.67M	79.42M	157.48M
Cash Flow
Free Cash Flow	-14.00K	-137.79M	-165.46M	-133.41M	-141.86M	-70.30M
Operating Cash Flow	35.07M	-44.65M	-78.48M	-75.13M	-73.32M	-46.41M
Investing Cash Flow	-41.42M	-93.14M	-141.97M	-58.28M	-157.76M	-23.86M
Financing Cash Flow	80.45M	56.21M	356.92M	31.23M	311.97M	130.83M

Alphatec Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATEC, the sentiment is Positive. The current price of 19.61 is above the 20-day moving average (MA) of 18.98, above the 50-day MA of 16.38, and above the 200-day MA of 13.08, indicating a bullish trend. The MACD of 1.12 indicates Positive momentum. The RSI at 65.19 is Neutral, neither overbought nor oversold. The STOCH value of 21.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATEC.

Alphatec Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	76 Outperform	$1.69B	24.33	18.31%	―	29.47%	23.24%
AHCO	72 Outperform	$1.23B	16.69	4.77%	―	-0.23%	―
AORT	61 Neutral	$2.11B	―	-2.45%	―	9.81%	-1067.00%
ATEC	58 Neutral	$2.91B	―	-540.40%	―	27.11%	17.66%
LIVN	58 Neutral	$2.94B	―	-17.63%	―	8.97%	-1024.86%
ESTA	55 Neutral	$1.43B	-16.14	-338.19%	―	24.76%	-10.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alphatec Holdings Corporate Events

Alphatec Holdings Mourns Loss of Board Member

On November 7, 2025, Alphatec Holdings announced the passing of Jeffrey P. Rydin, a respected member of its Board of Directors, who died on November 3, 2025, after a lengthy illness. Rydin, who joined ATEC in 2016, played a pivotal role in transforming the company’s sales channel and was instrumental in its turnaround efforts. His contributions were highly valued by the company, and his passing is deeply mourned by the ATEC community, highlighting his significant impact on the company’s culture and momentum.

The most recent analyst rating on (ATEC) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Alphatec Holdings stock, see the ATEC Stock Forecast page.

Alphatec’s Earnings Call: Strong Growth and Positive Outlook

Alphatec’s recent earnings call painted a picture of robust financial health and strategic growth, with the company showcasing significant revenue increases, enhanced surgeon engagement, and a solid cash flow position. Despite facing some challenges from tariffs and market disruptions, the overall sentiment was optimistic, underscoring a positive outlook for the future.

Alphatec Reports Strong Q3 2025 Revenue Growth

Alphatec Holdings, Inc., a medical device company specializing in innovative spine surgery solutions, has reported its financial results for the third quarter of 2025. The company, known for its focus on clinical distinction in spine surgery, operates primarily in the healthcare sector.